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Abstract
Background: There is evidence of increased low grade inflammation (LGI) in schizophrenia patients. However, the
inter-individual variation is large and the association with demographic, somatic and psychiatric factors remains
unclear. Our aim was to explore whether levels of the novel LGI marker soluble urokinase plasminogen activator
receptor (suPAR) were associated with clinical factors in schizophrenia and if such associations were sex-dependent.
Method: In this observational study a total of 187 participants with schizophrenia (108 males, 79 females)
underwent physical examination and assessment with clinical interviews (Positive and Negative Syndrome Scale
(PANSS), Calgary Depression Scale for Schizophrenia (CDSS), Alcohol Use Disorder Identification Test (AUDIT), and
Drug Use Disorder Identification Test (DUDIT)). Blood levels of suPAR, glucose, lipids, and high sensitivity C-reactive
protein (hsCRP) were determined and body mass index (BMI) calculated. Multivariable linear regression analyses
were used adjusting for confounders, and sex interaction tested in significant variables.
Results: Adjusting for sex, age, current tobacco smoking and BMI, we found that levels of hsCRP and depressive
symptoms (CDSS) were positively associated with levels of suPAR (p < 0.001). The association between suPAR and
CDSS score was significant in females (p < 0.001) but not in males. Immune activation measured by hsCRP was not
associated with depressive symptoms after adjusting for BMI.
Conclusion: Our findings indicate that increased suPAR levels are associated with depressive symptoms in females
with schizophrenia, suggesting aberrant immune activation in this subgroup. Our results warrant further studies,
including longitudinal follow-up of suPAR levels in schizophrenia and experimental studies of mechanisms.
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Background
Involvement of the immune system in the pathogenesis
of schizophrenia has been investigated for several de-
cades [1]. In this regard, immune-mediated mechanisms
seem to be relevant in the prenatal stage and also
through childhood and in adolescence and adulthood [2,
3]. Furthermore, immune disorders such as non-
neurological autoimmune diseases are associated with
increased risk of psychosis [4]. Genetic variants in the
immune system have also been implicated in the etiology
of schizophrenia, at least in a subgroup of patients (PGC
Nature 2014).
The overlap of symptoms in current diagnostic classifi-
cation makes research, diagnostics and treatment chal-
lenging [5]. Previous studies have suggested the
existence of subgroups with immune-dysregulation in
schizophrenia [1, 6], and other severe mental disorders
such as bipolar disorder [7] and major depressive dis-
order (MDD) [8, 9]. Further, analyses of postmortem
endothelial cells from schizophrenia patients with in-
creased inflammatory burden have revealed transcrip-
tional alterations associated with endothelial cell
dysregulation [10].
As a biomarker of inflammation, C-reactive protein
(CRP) has received much attention. Numerous studies
have evaluated levels of CRP as a means of identifying
inflammatory subgroups in schizophrenia, mostly
reporting modestly but significantly elevated levels
mainly related to the severity of symptoms occurring
during the relapsing phase [11]. However, despite be-
ing a robust biomarker, its role in schizophrenia is
not yet established. The association between CRP and
central obesity and infections further complicates in-
terpretation of CRP in the context of schizophrenia.
Thus, identification of biomarkers linked more specif-
ically to psychological state and pathophysiological
processes is warranted.
The urokinase plasminogen activator receptor (uPAR)
is a glycoprotein active across several systems (e.g. the fi-
brinolytic and inflammatory systems). Linked to the cell
surface via a glycosyl phosphatidylinositol anchor, uPAR
is found on a variety of cells, e.g. immune cells, endothe-
lial cells and neurons and involved in numerous inflam-
matory processes with effects on development of axons,
brain development and maturation as well as neuro re-
pair and neuroprotection [12–14]. Upon immune activa-
tion, uPAR can be shed from the plasma membrane, and
the resulting soluble uPAR (suPAR) can easily be mea-
sured in blood samples. The suPAR protein displays ro-
bust pre-analytic characteristics with regard to sampling,
storage and freeze-thaw cycles [15] as well as stability
beyond fasting and circadian rhythm [16]. LGI involving
suPAR is mainly associated with endothelial dysfunction
[12]. However, a small study found the suPAR gene
(PLAUR) to be upregulated in visceral fat in non-obese
patients with depression and/or anxiety [17].
Large population-based studies have revealed a posi-
tive association between blood levels of suPAR and the
following factors; female sex, increasing age, unhealthy
lifestyle, cardiovascular risk factors, diabetes, as well as
low socioeconomic status [18–20]. Additionally suPAR
levels are elevated in patients with MDD [21–24].
Levels of suPAR were significantly increased in hetero-
geneous samples of schizophrenia patients e.g. including
both sexes, alcohol and drug users as well as somatic
diseases [25, 26]. In contrast, no difference was found
between a homogenous males sample with acute phase
schizophrenia and healthy controls [27]. However, nei-
ther of these studies thoroughly investigated the poten-
tial associations between suPAR levels and clinical
characteristics, which may identify clinical subgroups as
suggested for other immune mechanisms [6, 28].
Since differentiation of both the immune system and
the central nervous system (CNS) reveal sex differences,
cross-talk between these two systems could contribute
to the sex differences observed in symptoms, cognition
and clinical features (e.g. age of onset, trajectory) in pa-
tients with schizophrenia [29, 30]. Sex differences in
suPAR levels have consistently been reported in larger
population studies [18, 20]. Due to the large heterogen-
eity in schizophrenia, identification of subsets of patients
could lead to higher precision in experimental studies of
underlying mechanisms as well as more individualized
diagnostics and treatment. The suPAR protein seems to
have potential to contribute to such subset
identification.
In the present study we aimed to identify whether clin-
ical factors, such as psychiatric symptoms and cardiovas-
cular risk factors, were associated with low grade
inflammation (LGI) measured by suPAR levels in partici-
pants with schizophrenia. Secondly, we wanted to inves-




Participants were recruited in the period 2003–2017 into
the collaborating projects Effects of Physical Activity in
Psychosis study (EPHAPS) [31] and Thematically Orga-
nized Psychosis (TOP) Research project/NORMENT
(Norwegian Centre for Mental Disorder Research) [7].
The recruitment was mainly from outpatient psychiatric
clinics from the southeast region of Norway. The study
was observational and the main inclusion criterion was
fulfilling the Diagnostic and Statistical Manual of Mental
Disorders (DSM) criteria for schizophrenia spectrum
disorder (4th and 5th edition), confirmed by the Struc-
tured Clinical Interview for DSM-IV (SCID-I). The
Bigseth et al. BMC Psychiatry          (2021) 21:527 Page 2 of 10
participants were 18–67 years of age, understood and
spoke a Scandinavian language, and had no mental re-
tardation. In order to exclude participants with severe
ongoing and acute infections, we excluded participants
with serum levels of CRP above 20mg/L. Most of the
current participants were included as cases in a previous
case-control study of suPAR levels (Bigseth et al. 2021).
However, in the current study we did not exclude partic-
ipants with comorbid chronic infectious and auto-
immune diseases to reflect a more naturalistic sample.
Assessments
Information and assessments were obtained or carried
out by trained clinicians. Diagnosis was confirmed using
the Structured Clinical Interview for DSM-IV axis I Dis-
orders, SCID-I, [32] and the trained clinicians in both
research groups (TOP/NORMENT and EPHAPS)
underwent a SCID-I training program lead by experts
from the University of California Los Angeles (UCLA).
Information on sociodemographics, medication, mental
and physical health was obtained through patient charts,
self-reports and interviews. For baseline assessment of
psychotic symptom levels, we used positive and negative
subscale of the Positive and Negative Syndrome Scale
(PANSS) [33]. The Calgary Depression Scale for Schizo-
phrenia (CDSS) [34], as well as the depression dimen-
sion (PANSS depressed factor) in the five factor model
of PANSS [35] were used to assess severity of depressive
symptoms. A cutoff score CDSS ≥6 was used for depres-
sion [34, 36]. Antipsychotic medication doses were
quantified by defined daily doses (DDD) according to
WHO standards (http://www.whocc.no/) and catego-
rized in either “no medication, low, moderate or high
metabolic risk” (see Supplementary Table C, Add-
itional File 3) [37]. We applied the AUDIT to assess al-
cohol use, and participants were categorized into a
group of “problematic use of alcohol” when scores were
above defined cutoff values (≥ 5 for females and ≥ 8 for
males). DUDIT was applied to assess substance use,
where “problematic use of drugs” was defined by cutoff
values (≥ 2 for females and ≥ 6 for males) [38]. We used
standardized assessment of blood pressure, and body
mass index (BMI) was calculated based on standardized
measurement of weight and height.
Blood samples
Fasting blood samples were collected in the morning
and subsequently analyzed according to pre-defined pro-
tocols. Soluble uPAR and hsCRP were measured in du-
plicate using a commercially available enzyme-
immunoassay (RnDSystems, Stillwater, MN, USA) in a
384-well format using the combination of a SELMA
(Jena, Germany) pipetting robot and a BioTek (Winoo-
ski, VT, USA) dispenser/washer. Absorption was read at
450 nm with wavelength correction set to 540 nm using
an ELISA plate reader (Bio-Rad, Hercules, CA, USA).
Intra- and inter-assay coefficients of variation were <
10% [25].
Blood triglycerides, HDL and glucose were analyzed
according to standardized procedures in the hospital lab
where blood was sampled. We used the Atherogenic
Index of Plasma ((AIP) = log(triglycerides/HDL-choles-
terol)) as a proxy for cardiovascular disease (CVD) risk
[39–41] and fasting glucose as a proxy for diabetes risk
(Table 2).
Statistics
Descriptive statistics of demographic and clinical vari-
ables were presented as frequencies and proportions for
categorical data and mean and standard deviation (SD)
or median and interquartile range (IQR) for continuous
data.
To identify factors associated with suPAR levels, we
performed linear regression analyses. Variables with
established association with suPAR (i.e. sex, age, current
tobacco smoking and BMI) were included in the model
regardless of the association with suPAR in our sample
[18, 42] and hsCRP was used to adjust for inflammatory
activity linked to different inflammatory pathways [12].
Because of the known association between age and LGI
and a wide age range of included participants, age was
adjusted for as a continuous variable, as was BMI and
hsCRP. Due to the restricted sample size variables with
less evidence from the literature (i.e. PANSS positive,
PANSS negative, CDSS, hsCRP, AIP, fasting glucose,
blood pressure, problematic use of alcohol and drugs,
level of education and antipsychotic medication (DDD
and metabolic risk level)) were included into the model
according to the purposeful selection approach [43]. In
brief, variables were included in the multivariable model
if univariable analyses showed p < 0.1. Then the variables
were removed one at a time, the one with the largest p-
value first, until all remaining variables were statistically
associated with the suPAR level. No outliers were identi-
fied. All continuous variables were examined and linear-
ity found satisfactory. We observed no multicollinearity
between the independent variables. Results are presented
as beta coefficients with 95% confidence intervals (CI)
and p-values.
To explore the possible effect modification by sex we
tested for interactions, on the multiplicative scale, be-
tween sex and all the included variables in the final
model. In the presence of a significant interaction, we
conducted stratified analysis by sex.
Several sensitivity analyses were performed to assess
the robustness of the results. To explore the impact of
the measurement tool, we substituted the CDSS sum
score by the CDSS cutoff score of ≥6 and subsequently
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PANSS depressed factor. Studying the dimensions of
CDSS, we replaced CDSS sum score with each separate
item of CDSS in the final model stratifying by sex. To
compare effects of inflammation associated with endo-
thelial dysfunction (suPAR) and inflammation associated
with central obesity and acute infection response
(hsCRP), we explored the relationship between hsCRP
and depressive symptoms for the whole sample and
stratified by sex. Post-hoc we investigated how levels of
suPAR could predict depression in schizophrenia in
males and females by constructing a Receiver Operating
Characteristic (ROC) curve, defining CDSS ≥6 as posi-
tive cases. Psychometric properties of the CDSS, such as
Cronbach’s alpha of internal consistency as well as asso-
ciations between measured symptoms are presented in
Supplementary Text 1, Additional File 4 and Supple-
mentary Table B1 and B2, Additional File 2.
Associations with p < 0.05 (two-tailed) were considered
significant in the main analyses, while the significance
level was set to 0.01 in additional analyses to reduce the
likelihood of type-I error. All statistical analyses were
performed in SPSS version 25 and STATA SE15.
Results
Participants characteristics and sex differences
The naturalistic schizophrenia sample consisted of both
males (n = 108) and females (n = 79), mean 32.6 years of
age (range 18–67), and included participants with comor-
bid alcohol and drug use. Females scored higher than
males on depression symptom scales, both the CDSS sum
score and the CDSS cutoff value (CDSS ≥6) (Table 1).
There were higher PANSS general scores in females com-
pared to males (mean difference = 2.70), in particular for
PANSS depressed factor (mean difference = 1.84).
Clinical somatic characteristics, blood indices and anti-
psychotic medication are presented in Table 2. Females
had lower AIP (mean difference = 0.15) and systolic
(mean difference = 9.42) and diastolic blood pressure
(mean difference = 4.23) compared to males. Levels of
suPAR were higher in females compared to males (mean
difference = 0.29).
Associations between suPAR and clinical factors
In the multivariable analyses we found that suPAR levels
were positively associated with female sex, age, current








Age [years], mean (SD) 32.6 (12.4) 32.0 (11.6) 33.5 (13.4)
aLevel of education
Low, n(%) 90 (48.1) 51 (47.2) 39 (49.4)
Medium, n(%) 73 (39.0) 43 (39.8) 30 (38.0)
High, n(%) 24 (12.8) 14 (13.0) 10 (12.7)
Ethnicity (caucasian), n(%) 177 (94.7) 102 (94.4)) 75 (95.0)
Current tobacco smoking, n(%) 102 (54.8) 60 (56.1) 42 (53.2)
bProblematic use of alcohol, n(%) 54 (30.0) 29 (27.9) 25 (32.9)
bProblematic use of drugs, n(%) 25 (13.9) 15 (14.4) 10 (13.2)
Psychiatric characteristics
PANSS positive, mean (SD) 15.8 (5.2) 15.4 (4.8) 16.3 (5.6)
PANSS negative, mean (SD) 17.5 (6.4) 18.1 (5.8) 16.6 (7.1)
PANSS general, mean (SD) 34.2 (8.7) 33.0 (7.8) 35.7 (9.7)
PANSS total, mean (SD) 67.5 (16.5) 66.6 (15.1) 68.7 (18.3)
PANSS depressed factor, mean (SD) 8.2 (3.3) 7.5 (3.1) 9.3 (3.4)
CDSS sum score, mean (SD) 5.4 (5.2) 4.3 (3.9) 7.0 (6.2)
CDSS ≥6, n(%) 73 (42.0) 34 (34.0) 39 (52.7)
cDuration of illness [years], median (IQR) 6.0 (2.0–14.0) 5.0 (2.0–13.8) 7.0 (2.0–14.5)
Admitted to hospital, n(%) 59 (32.4) 35 (33.3) 24 (31.2)
Note: SD standard deviation, IQR interquartile range (first quartile-third quartile). CDSS Calgary Depression Scale for Schizophrenia (0–27), PANSS Positive And
Negative Syndrome Scale (30–210), Missing data (above 5% of data points): CDSS n = 13, Duration of illness: n = 18
aCategorized as low (less than completed high school), medium (high school completed) and high (3 years or more of college or university education)
bProblematic use of alcohol when above defined cut-off values AUDIT (≥5 for females and ≥ 8 for males) and Problematic use of drugs when above defined cut-
off values for DUDIT (≥2 for females and ≥ 6 for males)cDuration of illness was calculated as age at inclusion minus age at onset of first psychotic episode
1t-test, 2Mann-Whitney U-test¸3Chi-squared test
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tobacco smoking, hsCRP and depressive symptoms
(CDSS sum score). In addition, BMI was negatively asso-
ciated with suPAR in the multivariable analyses (Table 3).
We found a statistically significant interaction between
sex and CDSS sum score (p = 0.03) and re-ran the final
model, stratified by sex. In males we found positive asso-
ciation between suPAR levels and age, current tobacco
smoking and hsCRP, while BMI was negatively associ-
ated with suPAR. Depressive symptoms however, were
not associated with suPAR in males. For females on the
other hand, depressive symptoms and current tobacco
smoking were positively associated with suPAR, but age,
hsCRP and BMI were not.
Sensitivity analyses
The sensitivity analyses supported the main finding of
the study. We found similar results for the associations
between clinical factors and suPAR levels when CDSS
sum score was substituted by CDSS cutoff score of ≥6
and subsequently PANSS depressed factor (for further
details see Supplementary Table A, Additional File 1).
Studying the separate CDSS items (C1-C9), for females
there were positive associations between suPAR and the
CDSS items C3 (self depreciation), C4 (guilty ideas of
reference), C5 (pathological guilt), C6 (morning depres-
sion), C7 (early wakening) and C8 (suicide). For C1 (self
described depression) and C2 (hopelessness) the associa-
tions were borderline significant and there was no asso-
ciation between suPAR levels and C9 (observed
depression), the only item based on the clinicians inter-
pretation. For males neither of the items were signifi-
cantly associated with suPAR levels (Table 4).
Levels of hsCRP and depression measures (CDSS sum
score, CDSS ≥6 and PANSS depressed factor) were not
significantly associated (see Supplementary Text 2, Add-
itional File 5). However, when stratifying by sex, there
was a borderline significant association between hsCRP
and CDSS sum score in females (beta 0.07, 95% CI 0.01
Table 2 Somatic characteristics in our sample of participants with schizophrenia
Characteristics Total sample (n = 187) Males (n = 108) Females (n = 79)
Somatic features
Body Mass Index[kg/m2], mean (SD) 28.5 (6.1) 28.1 (5.8) 29.0 (6.5)
Systolic blood pressure [mmHg], mean (SD) 126.1 (15.7) 130.2 (16.3) 120.8 (13.3)
Diastolic blood pressure [mmHg], mean (SD) 79.8 (10.6) 81.7 (11.0) 77.4 (9.6)
Blood indices
suPAR [ng/ml], mean (SD) 1.8 (0.6) 1.7 (0.5) 2.0 (0.6)
hsCRP [mg/L], mean (SD) 2.2 (1,5) 2.2 (1.4) 2,3 (1.5)
HDL cholesterol [mmol/L], mean (SD) 1.2 (0.4) 1.1 (0.3) 1.4 (0.4)
LDL cholesterol [mmol/L], mean, (SD) 3.0 (1.1) 3.0 (1.1) 3.0 (1.1)
Triglycerides [mmol/L], median (IQR) 1.4 (0.9–2.2) 1.5 (1.0–2.6) 1.3 (0.9–1.9)
Fasting glucose[mmol/L], mean (SD) 5.3 (0.9) 5.3 (0.8) 5.2 (1.1)
Atherogenic index of plasma, mean (SD) 0.1 (0.3) 0.2 (0.3) 0.0 (0.3)
Comorbid diseases
Cardiovascular disease, n (%) 21 (11.9) 13 (13.0) 8 (10.4)
Diabetes type II, n (%) 7 (4.0) 3 (3.0) 4 (5.2)
Infectious and autoimmune diseases, n (%) 12 (6.8) 7 (7.0) 5 (6.5)
Antipsychotic medication
Antipsychotic medication [DDD], mean (SD) 1.3 (1.0) 1.3 (1.0) 1.3 (1.0)
aAntipsychotic metabolic risk
No antipsychotic medication, n (%) 20 (10.7) 12 (11.1) 8 (10.1)
Low level, n (%) 27 (14.4) 15 (13.9) 12 (15.2)
Moderate level, n (%) 76 (40.6) 39 (36.1) 37 (46.8)
High level, n (%) 64 (34.2) 42 (38.9) 22 (27.8)
Note. suPAR soluble urokinase plasminogen activator receptor, hsCRP high sensitivity C-reactive protein, SD standard deviation, IQR interquartile range (first
quartile-third quartile), DDD defined daily doses
Missing data (above 5% of data points): BMI: n = 12, Systolic and diastolic blood pressure: n = 9, HDL-cholesterol: n = 16, LDL-cholesterol: n = 22, Triglycerides: n =
15, Fasting Glucose: n = 17, Cardiovascular disease: n = 10, Diabetes type II: n = 10, Infectious and autoimmune disease: n = 10
aAntipsychotic metabolic risk: See Table C in supplementary material
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to 0.13) but not in males. When adjusting for BMI the
association between hsCRP and CDSS sum score in fe-
males became clearly non-significant for females as well.
We found that suPAR levels could predict depression
(CDSS ≥6) in participants with schizophrenia to a lim-
ited extent only (Fig. 1).
Discussion
In the current study we investigated the association be-
tween LGI by suPAR levels and clinical factors in schizo-
phrenia. In multivariate analyses we found that sex, age,
current tobacco smoking, BMI, hsCRP and depressive
symptoms were significantly associated with levels of
suPAR. However, we found an interaction between sex
and CDSS, with positive association between CDSS sum
score and suPAR levels only in females. In contrast, LGI
reflected by hsCRP was not associated with depressive
symptoms in schizophrenia.
To our knowledge, the current study is the first to in-
vestigate the relationship between the LGI marker
suPAR and clinical symptoms in schizophrenia taking
several potential confounders into account. Our results
Table 3 Factors associated with suPAR (ng/ml) in participants with schizophrenia
Univariable regression Multivariable regression
(n = 163)a
Multivariable regression
Males (n = 91)a
Multivariable regression
Females (n = 72)a
β 95% CI p β 95% CI p β 95% CI p β 95% CI p
Female sex 0.29 0.13 to 0.46 0.001 0.26 0.11 to 0.40 0.001 – – – – – –
Age (per 10 years) 0.08 0.01 to 0.15 0.02 0.09 0.03 to 0.15 0.003 0.11 0.03 to 0.19 0.006 0.08 −0.02 to 0.18 0.11
Tobacco smoking 0.33 0.17 to 0.49 <
0.001
0.30 0.16 to 0.45 <
0.001
0.20 0.01 to 0.38 0.04 0.39 0.16 to 0.63 0.001
hsCRP (mg/L) 0.13 0.08 to 0.18 <
0.001
0.12 0.06 to 0.18 <
0.001
0.13 0.05 to 0.20 0.001 0.08 −0.01 to 0.17 0.07
BMI (per 5 kg/m2) 0.05 −0.03 to
0.12
0.21 −0.08 − 0.15 to −
0.01
0.03 −0.10 − 0.19 to −
0.01
0.03 −0.05 − 0.17 to
0.06
0.37
CDSS sum score 0.04 0.02 to 0.05 <
0.001
0.03 0.02 to 0.05 <
0.001
0.01 −0.02 to 0.03 0.48 0.04 0.02 to 0.06 <
0.001
AIP 0.36 0.11 to 0.62 0.005 – – – – – – – – –
Glucose (mmol/L) 0.09 −0.01 to
0.19





0.097 – – – – – – – – –
Note: suPAR soluble urokoinase Plasminogen Activator Receptor; CI Confidence Interval, β = beta coefficient, hsCRP high sensitivity C-reactive protein, BMI Body
Mass Index, AIP Atherogenic Index of plasma calculated as log10(Triglycerids/HDL-cholesterol), CDSS Calgary Depression Scale for Schizophrenia (0–27),
Problematic use of drugs = above defined cut-off values for Drug Use Disorders Identification Test (DUDIT) (≥2 for females and ≥ 6 for males)
aMulitvariable regression model including all variables listed. The amount of explained variance by the model (adjusted R2) was 0.35 for whole sample, 0.20 in
males and 0.37 in females





Items of CDSS interview βa CI p βa 95% CI p
C1: Self described depression −0.02 − 0.13 to 0.09 0.75 0.20 0.05 to 0.35 0.012
C2: Hopelessness 0.04 −0.08 to 0.16 0.47 0.20 0.05 to 0.36 0.011
C3: Self depreciation 0.03 −0.08 to 0.13 0.61 0.20 0.07 to 0.32 0.002
C4: Guilty ideas of reference 0.19 0.03 to 0.35 0.02 0.21 0.06 to 0.36 0.006
C5: Pathological guilt 0.09 −0.09 to 0.26 0.34 0.22 0.10 to 0.35 0.001
C6: Morning depression 0.01 −0.12 to 0.15 0.86 0.22 0.07 to 0.36 0.004
C7: Early wakening 0.07 −0.05 to 0.19 0.27 0.18 0.06 to 0.31 0.005
C8: Suicide −0.17 − 0.34 to − 0.00 0.045 0.31 0.13 to 0.48 0.001
C9: Observed depression 0.06 −0.10 to 0.22 0.44 0.13 −0.07 to 0.32 0.21
Note: suPAR soluble urokinase Plasminogen Activator Receptor (ng/ml), CDSS Calgary Depression Scale for Schizophrenia (0–27), CI Confidence Interval, β = beta
coefficient, CI confidence interval
aAdjusted for age, current tobacco smoking, high sensitivity C-reactive protein and body mass index
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are not surprising as prior studies have shown associa-
tions between other pro-inflammatory cytokines and
symptom severity in schizophrenia [44] and depressive
symptoms in first episode psychosis [45]. Also, a recent
study indicated that a decrease in Interleukin-6, a pro-
inflammatory cytokine, was associated with a decrease in
depressive symptoms in first episode schizophrenia pa-
tients [46]. Moreover, results from non-schizophrenia
samples show an association between suPAR levels and
depression [21–24].
In schizophrenia, prevalence of depression ranges from
30 to 60% [47–49] and with great variation between dif-
ferent subpopulations. Depression in our sample was
comparable to these levels, also the female overrepresen-
tation of depressive symptoms was in line with studies
in the general population, [50, 51]. The sensitivity-
analysis, substituting every single CDSS item with the
sum score, demonstrated that no particular item or item
cluster drove the association with suPAR levels in
females.
Interestingly, suPAR levels were significantly associ-
ated with depressive symptoms in females only, while a
follow-up study to Bot et al. (2015) patients with MDD
indicated a positive association between suPAR levels
and depression in males only [21, 52]. We are not able
to explain this difference fully, but Ramsey et al. 2016
analyzed 171 different proteins in serum and included
MDD per diagnosis, while in our study, we investigated
primarily suPAR, and adjusted for hsCRP in plasma in
participants with schizophrenia diagnose when measur-
ing depressive symptoms (not MDD per diagnosis).
As increased suPAR levels reflect inflammation and
are found to be associated with endothelial dysfunction,
one could speculate that there is an association between
suPAR levels and neuro-inflammation through endothe-
lial cell dysfunction in the microvasculature of the brain
[10, 53] as well as impaired neuro repair [13].
Depressive symptoms appear to play a part in the tran-
sition to first episode psychosis and seem to be a pre-
dictive factor of the outcome of schizophrenia [49].
Immune system aberrancies are associated with both
schizophrenia and depression [8]. Our results indicate
immune pathology is associated with depressive symp-
toms in females with schizophrenia. However, the results
are explorative and need to be confirmed. The ROC ana-
lyses showed that suPAR could not predict depression in
females with schizophrenia at a high enough level to use
it as a sole biomarker, yet the strong association with de-
pression should be further investigated in schizophrenia
as suPAR could have potential as an early indicator of
poorer outcome.
Sex, age, smoking and BMI are considered relevant ad-
justment factors in suPAR studies, and the current full
sample multivariate analysis revealed that these variables
were significantly associated with suPAR levels. The as-
sociation between BMI and suPAR was negative in the
multivariable analysis. Possible explanations for these
findings are that BMI does not accurately reflect fat dis-
tribution, and we adjusted for hsCRP, which is a marker
associated with central fat related inflammation as well
as acute infection [54]. Also, the suPAR gene (PLAUR)
is found to be upregulated in visceral fat of non-obese
participants with mood disturbances and/or anxiety.
However, it is uncertain to what degree circulating
uPAR is affected by this, and the statistical power was


































Diagonal segments are produced by ties.
Fig. 1 Receiver Operating Curves for suPAR vs depression. ROC curve suPAR vs depression defined as CDSS sum-score ≥ 6, stratified by sex. Males:
Positive cases n = 34, negative cases n = 66. AUC = 0.47 (95% CI: 0.35 to 0.60). Females: Positive cases n = 39, negative cases n = 35. AUC = 0.78
(95% CI: 0.67 to 0.88)
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associations between suPAR and the proxies for CVD
risk and Diabetes Mellitus Type II in the multivariate re-
gression in our sample, plus we adjusted for hsCRP (a
risk factor for CVD). This indicates that the association
between suPAR and depression is strong, even in the
presence of somatic disease.
The result of this study should be interpreted within
its limitations; the sample size, especially when stratify-
ing by sex, limited our possibilities to examine more fac-
tors with possible association with suPAR. It is also
important to emphasize the exploratory nature of our
study. Our focus was on the schizophrenia diagnosis,
and we had only symptom measures for depression.
However, the association between depressive symptoms
and suPAR levels was highly significant in females and
the sensitivity analyses revealed similar results. Including
a naturalistic sample increased the risk of comorbid
somatic diseases and medication affecting the immune
system and thus may bias the results of our study. How-
ever, schizophrenia patients are a heterogeneous group
with more prevalent comorbidity and medication com-
pared to the healthy population [55]. The participants
were recruited over a lengthy period and prevalence of
some characteristics may have changed over this period,
e.g. smoking habits, attention to healthy diet and phys-
ical activity.
When it comes to strengths, it is worth noting that
our study consisted of a relatively large, well-
characterized and heterogeneous sample. Thus, we were
able to adjust for many of the important factors associ-
ated with suPAR. Our study included participants of
both sexes and participants with known use of alcohol
and drugs, thus being a naturalistic sample and reducing
selection bias.
Conclusion
We found that depressive symptoms in female patients
with schizophrenia were significantly associated with
suPAR levels after adjusting for confounding factors and
inflammation by hsCRP. Our results suggest that im-
mune processes measured by suPAR but not hsCRP,
could be involved in the psychopathology in females
with schizophrenia and depressive symptoms. Larger
and longitudinal studies are warranted to confirm the
present findings and identify the specific immune mech-
anisms related to elevated suPAR levels in
schizophrenia.
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